Anti-TFPI Antibody (R1N06)

Catalog No.

RHC82802

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

WB: 1:1000-1:2000

Target

Extrinsic pathway inhibitor, Lipoprotein-associated coagulation inhibitor, TFPI, EPI, LACI, TFPI1, Tissue factor pathway inhibitor

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P10646

Applications

WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R1N06

Evaluating the Safety and Efficacy of Concizumab in Hemophilia A/B Patients: A Systematic Review., PMID:40368339

Revolutionizing Treatment Strategies through Inhibition of Tissue Factor Pathway Inhibitor: A Promising Therapeutic Approach for Hemophilia Management., PMID:40200623

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review., PMID:39971274

Marstacimab: First Approval., PMID:39715914

Examining downstream effects of concizumab in hemophilia A with a mathematical modeling approach., PMID:39536817

Functionally distinct anticoagulant mechanisms of endothelial cells., PMID:39522336

FDA approves first anti-TFPI antibody for haemophilia A and B., PMID:39478181

[Advances in hemophilia treatment]., PMID:39358264

Deletion of tissue factor pathway inhibitor isoform beta or gamma, but not alpha, improves clotting in hemophilic mice., PMID:38925489

Minimal interference of concizumab with standard clinical coagulation laboratory assays - An in vitro study., PMID:38924198

Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study., PMID:38880178

Concizumab improves clot formation in hemophilia A under flow., PMID:38815755

Impact of tissue factor expression and administration routes on thrombosis development induced by mesenchymal stem/stromal cell infusions: re-evaluating the dogma., PMID:38414067

Unfolded Von Willebrand Factor Binds Protein S and Reduces Anticoagulant Activity., PMID:38370737

TFPIα anticoagulant function is highly dependent on protein S in vivo., PMID:38306422

Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab., PMID:37776978

Activated protein C, protein S, and tissue factor pathway inhibitor cooperate to inhibit thrombin activation., PMID:37660436

Evolution of Antidrug Antibody Assays During the Development of Anti-Tissue Factor Pathway Inhibitor Monoclonal Antibody Marstacimab., PMID:37610502

Concizumab: First Approval., PMID:37341887

Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency., PMID:36696199

Absence of Effect of Emicizumab on D-Dimer Concentrations in Adult Patients with Severe Hemophilia A., PMID:36474347

SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people., PMID:36448024

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia., PMID:35999026

Human IL-17 and TNF-α Additively or Synergistically Regulate the Expression of Proinflammatory Genes, Coagulation-Related Genes, and Tight Junction Genes in Porcine Aortic Endothelial Cells., PMID:35844613

Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome., PMID:35838333

Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis., PMID:35667016

Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient's Perspectives., PMID:35465188

Revised model of the tissue factor pathway of thrombin generation: Role of the feedback activation of FXI., PMID:35352494

Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model., PMID:35316941

Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy., PMID:35279938

Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis., PMID:35102689

Clinical Utility of Subcutaneous Factor VIII Replacement Therapies in Hemophilia A: A Review of the Evidence., PMID:34908888

Factor V east Texas variant causes bleeding in a three-generation family., PMID:34847292

Resistance to activated protein C and impaired TFPI activity in women with previous hormone-induced venous thromboembolism., PMID:34634502

Evaluation of the efficacy of a novel Vibrio vulnificus vaccine based on antibacterial peptide inactivation in turbot, Scophthalmus maximus., PMID:34509628

Pulmonary coagulation and fibrinolysis abnormalities that favor fibrin deposition in the lungs of mouse antibody-mediated transfusion-related acute lung injury., PMID:34165170

Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management., PMID:34026796

An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency., PMID:33915599

Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody., PMID:33846873

Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia., PMID:33664415

Concizumab: a novel anti-TFPI therapeutic for hemophilia., PMID:33570646

Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics., PMID:33448093

MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia., PMID:33313469

Yersinia pestis Plasminogen Activator., PMID:33202679

[Analysis of Transfusion Therapy Effectiveness in Patients with Myelodysplastic Syndrome]., PMID:33067968

A new hybrid immunocapture bioassay with improved reproducibility to measure tissue factor-dependent procoagulant activity of microvesicles from body fluids., PMID:33038585

Proteomic identification of Placental Protein 1 (PP1), PP8, and PP22 and characterization of their placental expression in healthy pregnancies and in preeclampsia., PMID:32747003

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges., PMID:32726826

Liver gene regulation of hemostasis-related factors is altered by experimental snake envenomation in mice., PMID:32479494

Document Download

Anti-TFPI Antibody (R1N06).pdf